Cranberry, Hibiscus, and Vitamin C Extracts Versus Placebo in Latency of Premature Rupture of Membranes.

NCT ID: NCT06788132

Last Updated: 2025-09-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

84 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-30

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this clinical trial is to evaluate the effect of cranberry, hibiscus and vitamin C extracts supplementation on the duration of the latency of premature rupture of membranes in pregnant women between 24 and 34 weeks with PROM compared to placebo administration through a randomized double-blind clinical trial, which will be carried out from July to December 2024 in the pathological hospitalization ward of the Hospital Materno Infantil, with a sample of 84 pregnant women, divided into 2 equal groups (A and B), a control group and a placebo group, where 1 capsule per day will be administered, containing a combination of blueberry extract 100mg equivalent 36 mg, hibiscus extract 20 mg, vitamin C 500 mg with lactobacillus 200 MU or a starch capsule for 10 days. In addition, routine complementary studies will be carried out and through descriptive statistics using Redcap for data tabulation and analysis, it will be possible to prove or reject the hypothesis that proposes that the use of cranberry, vitamin C and Hibiscus supplementation does not prolong the latency of premature rupture of membranes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Premature Rupture of Membranes (PROM) is the loss of the integrity of the amniotic membranes, which includes amniotic fluid leakage via the transvaginal route and manifests itself prior to the onset of labor. It has a worldwide prevalence between 2 and 4% as a complication of pregnancies, which means that it plays an important role in preterm births and maternal-fetal complications as it is a very frequent identifiable factor. Latin America is no exception, Peru has reported up to 0.31% of the total morbidities attended in the Emergency Obstetric Service. Its management can vary from expectant, pharmacological to surgical depending on factors associated with the mother and the product, for example, gestational age, clinical condition of the mother, toxic habits, among others. Epidemiological studies carried out in Mexico explain a series of factors that increase the risk of PROM. These include: maternal reproductive tract infections (bacterial vaginitis, trichomonas, gonorrhea, chlamydia and occult chorioamnioitis); behavioral factors (smoking, substance abuse, nutritional status and sexual relations); obstetric complications (multiple pregnancy, polyhydramnios, cervical incompetence, hemorrhage during pregnancy and trauma during pregnancy), as well as environmental changes (barometric pressure). On the other hand, the results of epidemiological, clinical, histological, microbiological and molecular biology studies support that focal infection and inflammation play a primary and secondary role in the pathogenesis of PROM. In 2001, the article Frequency of premature rupture of membranes in preterm labor and evaluation of short and long term management protocols in the labor and delivery room of the Honduran Institute of Social Security was published, which reported a prevalence of 20% of this condition in the study population.7% of this condition in the population studied, a situation that has improved and by 2016 the national document on Initial management and referral of obstetric and neonatal complications was adopted, which includes premature rupture of membranes and establishes a prevalence of 10% of pregnancies and 20% of cases occur in preterm gestations. PROM in preterm pregnancies is the cause of one third of preterm births and 10% of perinatal deaths; it is also associated with an increase in maternal infectious morbidity due to chorioamnionitis and puerperal infection, constituting a problem for the national health system. The present research is aimed at the interpretation and analysis of the effects observed in two groups of pregnant women diagnosed with premature rupture of membranes after the administration of cranberry extract, hibiscus and vitamin C in comparison with a group that will be administered placebo, which is consider important to know in view of the high prevalence of this pathology in our environment, since through the results new guidelines could be developed in its management that are cost effective and adapted to the availability of our institutional resources and to the condition of each patient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Premature Rupture of Membranes Fetal Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

randomized, controlled, prospective, prospective, single-center, double-blind, parallel group, efficacy and superiority clinical trial
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
randomized, controlled, prospective, prospective, single-center, double-blind, parallel group, efficacy and superiority clinical trial

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cranberry, hibiscus and vitamin c extracts

1 capsule per day will be administered, containing a combination of blueberry extract 100mg equivalent 36 mg, hibiscus extract 20 mg, vitamin C 500 mg with lactobacillus 200 MU for 10 days

Group Type EXPERIMENTAL

Cranberry products

Intervention Type COMBINATION_PRODUCT

One capsule of cranberry extract 100mg equivalent 36 mg, hibiscus extract 20 mg, vitamin C 500 mg with lactobacillus 200 MU per day for 10 days

Starch

One capsule of Starch per day for 10 days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Starch one capsule per day for 10 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cranberry products

One capsule of cranberry extract 100mg equivalent 36 mg, hibiscus extract 20 mg, vitamin C 500 mg with lactobacillus 200 MU per day for 10 days

Intervention Type COMBINATION_PRODUCT

Placebo

Starch one capsule per day for 10 days

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who agree to participate in the study.
* Patients who sign the informed consent form.
* Patients who can read and write.
* Patients without alterations in the cognitive system.
* Patients who had their delivery at the Maternal and Child Hospital.
* Patients with admission criteria for conservative management in the pathology ward of the Hospital Escuela.
* Patients with a single non-abnormal fetus.
* Premature rupture of membranes with pregnancy of \>24.0 and \<34.0 weeks of gestation.

Exclusion Criteria

* Patients who do not wish to participate in the study
* Fetus with pulmonary anomalies, central nervous system and cardiopathies.
* Patient with chorioamnionitis.
* Premature rupture of membranes experienced within 14 days after amniocentesis or cervical cerclage placement.
* Multiple gestation.
* Delivery within 24 hours after admission.
* Intrauterine fetal death at presentation.
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universidad Nacional Autonoma de Honduras

OTHER

Sponsor Role collaborator

Ricardo A Gutierrez Ramirez, MD, MSc, FACOG

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ricardo A Gutierrez Ramirez, MD, MSc, FACOG

Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ricardo A. Gutierrez Ramirez, MD, MSc.

Role: STUDY_DIRECTOR

Universidad Nacional Autonoma de Honduras

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Escuela

Tegucigalpa, Francisco Morazán Department, Honduras

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Honduras

References

Explore related publications, articles, or registry entries linked to this study.

Gungorduk K, Asicioglu O, Gungorduk OC, Yildirim G, Besimoglu B, Ark C. Does vitamin C and vitamin E supplementation prolong the latency period before delivery following the preterm premature rupture of membranes? A randomized controlled study. Am J Perinatol. 2014 Mar;31(3):195-202. doi: 10.1055/s-0033-1343774. Epub 2013 Apr 16.

Reference Type BACKGROUND
PMID: 23592317 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PGO-UNAH-48-5-2025

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.